Twist Bioscience (TWST) Operating Expenses (2017 - 2026)

Twist Bioscience has disclosed Operating Expenses across 10 years of filings, most recently posting $156.6 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 16.54% year-over-year to $156.6 million; the TTM figure through Mar 2026 stood at $548.3 million (changed 0.1% YoY), while the FY2025 annual figure was $512.8 million, down 3.93% from the prior year.
• Operating Expenses improved to $156.6 million in Q1 2026, from $136.6 million in the prior quarter.
• Over the last five years, Operating Expenses for TWST reached as high as $170.4 million in Q2 2024 and fell as low as $98.9 million in Q4 2022.
• The 5-year median for Operating Expenses is $123.4 million (2024), against an average of $126.0 million.
• Annual changes were most pronounced in 2022 — Operating Expenses jumped 57.39% — and 2025, when it slipped 25.95%.
• A 5-year view of Operating Expenses shows it stood at $98.9 million in 2022, then gained by 19.83% to $118.5 million in 2023, then climbed by 4.12% to $123.4 million in 2024, then advanced by 10.73% to $136.6 million in 2025, then rose by 14.63% to $156.6 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $156.6 million, $136.6 million, and $128.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.